Program
gepotidacin
Also written as “Gepotidacin”, “GSK2140944” and “Gepotidacin Capsule”.
Its studies are mostly in Bacterial Infections · Urinary Tract Infections · Respiratory Tract Infections · Gonorrhea, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 232 open or running | phase 3since Jul 2, 2019 | Mar 29, 2012 | May 17, 2027phase 1 · NCT07645235 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Mar 29, 2012.
- Nov 17, 2014Phase 2 study in GonorrheaNCT02294682 · 106 enrolled · United States, Puerto Rico, United Kingdom
- Mar 31, 2016Phase 1 study in Bacterial InfectionsNCT02729038 · 32 enrolled · United States
- Jul 29, 2016Phase 1 study in Bacterial InfectionsNCT02853435 · 48 enrolled · United States
- May 15, 2018Phase 1 study in Bacterial InfectionsNCT03562117 · 25 enrolled · United States
- Jun 11, 2018Phase 2 study in Bacterial InfectionsNCT03568942 · 22 enrolled · United States
- Jul 2, 20192 phase 3 studiesNCT04010539, NCT04020341
- Sep 3, 2019Phase 1 study in Bacterial InfectionsNCT04079790 · 34 enrolled · United States
- Dec 3, 2019Phase 3 study in Urinary Tract InfectionsNCT04187144 · 1,606 enrolled · United States, Australia, Bulgaria and more
- Jul 28, 2020Phase 1 study in Bacterial InfectionsNCT04493931 · 64 enrolled · United States
- Feb 28, 2022Phase 1 study in Healthy VolunteersNCT05271799 · 24 enrolled · United States
- Nov 23, 2022Phase 3 study in Urinary Tract InfectionsNCT05630833 · 380 enrolled · Japan
- Sep 3, 2024Phase 3 study in Urinary Tract InfectionsNCT06597344 · 97 enrolled · United States
- Jan 19, 2026Phase 1 study in Urinary Tract InfectionsNCT07371429 · 25 planned · United States
- Jun 8, 2026Phase 1 study in Urinary Tract InfectionsNCT07645235 · 8 planned · United States
Ahead
- May 17, 2027Primary completion: phase 1 study in Urinary Tract InfectionsNCT07645235
- Aug 23, 2027Primary completion: phase 1 study in Urinary Tract InfectionsNCT07371429
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07645235Urinary Tract Infections · United States | 1 | Recruiting | May 17, 2027 | 8 |
| NCT07371429Urinary Tract Infections · United States | 1 | Not yet recruiting | Aug 23, 2027 | 25 |
| NCT06597344Urinary Tract Infections · United States | 3 | Completed | Mar 10, 2025 | 97 |
| NCT05630833Urinary Tract Infections · Japan | 3 | Completed | Feb 2, 2024 | 380 |
| NCT05271799Healthy Volunteers · United States | 1 | Completed | Apr 22, 2022 | 24 |
| NCT04493931Bacterial Infections · United States | 1 | Completed | Dec 21, 2020 | 64 |
| NCT04187144Urinary Tract Infections · United States, Australia, Bulgaria and more | 3 | Completed | Dec 1, 2022 | 1,606 |
| NCT04079790Bacterial Infections · United States | 1 | Completed | Nov 25, 2019 | 34 |
| NCT04020341Urinary Tract Infections · United States, Bulgaria, Czechia and more | 3 | Completed | Nov 30, 2022 | 1,531 |
| NCT04010539Gonorrhea · United States, Australia, Germany and more | 3 | Completed | Oct 10, 2023 | 628 |
| NCT03568942Bacterial Infections · United States | 2 | Completed | Jan 7, 2019 | 22 |
| NCT03562117Bacterial Infections · United States | 1 | Completed | Dec 26, 2018 | 25 |
| NCT02853435Bacterial Infections · United States | 1 | Completed | Oct 17, 2017 | 48 |
| NCT02729038Bacterial Infections · United States | 1 | Completed | Jun 20, 2017 | 32 |
| NCT02294682Gonorrhea · United States, Puerto Rico, United Kingdom | 2 | Completed | Jul 1, 2016 | 106 |
| NCT02257398Respiratory Tract Infections · United States | 1 | Completed | Mar 2, 2015 | 55 |
| NCT02045849Bacterial Infections · United States | 1 | Completed | Aug 21, 2014 | 46 |
| NCT02045797Bacterial Infections · United States | 2 | Completed | Jun 29, 2015 | 126 |
| NCT02000765Respiratory Tract Infections · United Kingdom | 1 | Completed | Nov 30, 2013 | 6 |
| NCT01934205Bacterial Infections · United States | 1 | Completed | Dec 21, 2013 | 22 |
| NCT01706315Respiratory Tract Infections · United States | 1 | Completed | Dec 13, 2013 | 72 |
| NCT01615796Respiratory Tract Infections · Australia | 1 | Completed | Feb 21, 2014 | 86 |
| NCT02202187Respiratory Tract Infections · United States | 1 | Completed | Feb 15, 2012 | 48 |
How it is read
Names in the registry
- “Gepotidacin”, 13 entries
- “GSK2140944”, 4 entries
- “Gepotidacin Capsule”, 1 entry
- “GSK2140944 Lyophile”, 1 entry
- “GSK2140944 Capsules”, 1 entry
Codes read as this program: GSK2140944.
Conditions, from the studies’ own filings
- Bacterial Infections, 9 studies
- Urinary Tract Infections, 6 studies
- Respiratory Tract Infections, 5 studies
- Gonorrhea, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.